Zhaomin Song, Zifeng Liu, Chenghui Yin, Jiali Yang, Xun Peng, Peili Zhao, Xiaolin Lang
Third Hospital of Qinhuangdao city, China.
The Shandong province Zibo City Qidu hospital, Qinhuangdao City Third Hospital Road, Haigang district the founding of Hebei city of Qinhuangdao province No. 222, zip code 066000 China.
Open Med (Wars). 2015 Dec 17;10(1):434-439. doi: 10.1515/med-2015-0075. eCollection 2015.
The feasibility of transcatheter arterial chemo-embolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. 30 cases receiving TACE were denoted the TACE group, another 30 cases receiving TACE combined with an intratumoral multi-point injection of cisplatin were denoted the TACE/cisplatin group. Cases with partial remission/complete remission (PR/CR) were analyzed using 2 tests; alpha fetoprotein (AFP), aspartate amino transferase (AST), total bilirubin (TBIL), erythrocyte, and platelet levels were detected and the differences between two groups were analyzed using the Student's t-test; cases with complications, including intrahepatic metastasis (IM), upper gastrointestinal bleeding (UGB), and liver failure were also counted. The correlation of clinical parameters with PR/CR was analyzed using multifactorial correlation analysis. Cases with PR/CR in the TACE/cisplatin group were significantly more than in TACE group, accompanied by significant declination in FAP. There were no significant differences of AST, ALT, TBIL, blood urea nitrogen (BUN), white blood cells (WBC), red blood cells (RBC), and platelets (PLT) between two groups; 3 cases with IM, one case with UGB and one case with LF were found in the TACE group, but only 1 case with IM was found in the TACE/cisplatin group. In addition, tumor stage was correlated with PR/CR. We concluded that TACE combined with intratumoral injection of cisplatin was more effective than TACE, and with fewer complications and side effects.
经导管动脉化疗栓塞术（TACE）联合瘤内注射顺铂治疗肝细胞癌的可行性。将30例行TACE治疗的患者设为TACE组，另30例行TACE联合瘤内多点注射顺铂的患者设为TACE/顺铂组。采用2检验分析部分缓解/完全缓解（PR/CR）病例；检测甲胎蛋白（AFP）、天冬氨酸转氨酶（AST）、总胆红素（TBIL）、红细胞和血小板水平，并采用学生t检验分析两组间差异；统计包括肝内转移（IM）、上消化道出血（UGB）和肝衰竭在内的并发症病例。采用多因素相关性分析临床参数与PR/CR的相关性。TACE/顺铂组PR/CR病例显著多于TACE组，同时FAP显著下降。两组间AST、ALT、TBIL、血尿素氮（BUN）、白细胞（WBC）、红细胞（RBC）和血小板（PLT）无显著差异；TACE组发现3例IM、1例UGB和1例LF，而TACE/顺铂组仅发现1例IM。此外，肿瘤分期与PR/CR相关。我们得出结论，TACE联合瘤内注射顺铂比TACE更有效，且并发症和副作用更少。
